Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
Aligos Therapeutics (ALGS) was upgraded by Jefferies Financial Group Inc. to "strong-buy".
Aligos Therapeutics (ALGS) is now covered by Westpark Capital. They set a "buy" rating and a $48.00 price target on the stock.
Aligos Therapeutics (ALGS) was upgraded by Jefferies Financial Group Inc. to "strong-buy".